Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Immunoglobulin G (IgG), primarily administered as intravenous immunoglobulin (IVIG), has substantial scientific validation for its use in treating certain autoimmune disorders. IVIG is a blood product containing pooled IgG antibodies derived from thousands of healthy donors. Its use is well-established for autoimmune conditions such as immune thrombocytopenic purpura (ITP), Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis, among others. The mechanism involves multiple immunomodulatory effects, including suppression of pathogenic autoantibodies, modulation of Fc receptor function, neutralization of complement activation, and alteration of cytokine production. Large randomized controlled trials and systematic reviews support its efficacy, particularly in acute and severe autoimmune settings where rapid immunosuppression is needed or when first-line treatments (e.g., corticosteroids) fail or are contraindicated.

Both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved IVIG for several autoimmune indications. Guidelines from major medical organizations recommend IVIG as a first- or second-line therapy for specific autoimmune diseases. Despite its high cost and potential adverse effects, IVIG remains a key therapeutic option because of its broad immunomodulatory properties and established clinical benefit.

In summary, the use of Immunoglobulin G (as IVIG) in autoimmune disorders is strongly rooted in scientific evidence, reflected by regulatory approvals and clinical guidelines.

More about Immunoglobulin G
More about Autoimmune Disorders

Other ingredients used for Autoimmune Disorders

Other health conditions supported by Immunoglobulin G

Products containing Immunoglobulin G